

1. ***The MSBase pregnancy, neonatal outcomes, and women's health registry.*** Jokubaitis, VG. Skibina, O. Alroughani, R. Altintas, A. Butzkueven, H. Eichau, S. Fragoso, Y. Hellwig, K. Hughes, S. Rath, L. Van der Walt, A. Gray, O. *Ther Adv Neurol Disord.* (Apr 2021) 14: 1-8. doi: 10.1177/17562864211009104.
2. ***Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis.*** Yeh, W.Z. Widyastuti, P.A. Van der Walt, A. Stankovich, J. Havrdova, E. Horakova, D. Vodehnalova, K. Ozakbas, S. Eichau, S. Duquette, P. Kalincik, T. Patti, F. Boz, C. Terzi, M. Yamout, B.I. Lechner-Scott, J. Sola, P. Skibina, O.G. Barnett, M. Onofrj, M. José Sá, M. McCombe, P. Grammond, P. Ampapa, R. Grand'Maison, F. Bergamaschi, R. Spitaleri, D. Van Pesch, V. Cartechini, E. Hodgkinson, S. Soysal, A. Saiz, A. Gresle, M. Uher, T. Maimone, D. Turkoglu, R. Hupperts, R. Amato, MP. Granella, F. Oreja-Guevara, C. Altintas, A. Macdonell, R. Castillo-Trivino, T. Butzkueven, H. Alroughani, R. Jokubaitis, V.G. and the MSBase Study Group. *Neurology.* doi: 10.1212/WNL.000000000012084. [Online ahead of print – Apr 2021].
3. ***Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.*** Butzkueven, H. Spelman, T. Horakova, D. Hughes, S. Solaro, C. Izquierdo, G. Havrdová, E.K. Grand'Maison, F. Prat, A. Girard, M. Hupperts, R. Onofrj, M. Lugesesi, A. Taylor, B. and the MSBase Study Group. Giovannoni, G. Kappos, L. Hauser, S.L. Montalban, X. Craveiro, L. Freitas, R. Model, F. Overell, J. Muros-Le Rouzic, E. Sauter, A. Wang, Q. Wormser, D. Wolinsky, J.S. *Eur. J. Neurol.* doi: 10.1111/ene.14824. [Online ahead of print – Mar 2021].
4. ***Determinants of therapeutic lag in multiple sclerosis.*** Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Debouverie, M. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Edan, G. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugesesi, A. Grammond, P. Ciron, J. Ruet, A. Ozakbas, S. De Seze, J. Louapre, C. Zephir, H. José Sá, M. Sola, P. Ferraro, D. Labauge, P. Defer, G. Bergamaschi, R. Lebrun-Frenay, C. Boz, C. Cartechini, E. Moreau, T. Laplaud, D. Lechner-Scott, J. Grand'Maison, F. Gerlach, O. Terzi, M. Granella, F. Alroughani, R. Iuliano, G. Van Pesch, V. Van Wijmeersch, B. Spitaleri, D. Soysal, A. Berger, E. Prevost, J. Aguera-Morales, E. McCombe, P. Castillo Triviño, T. Clavelou, P. Pelletier, J. Turkoglu, R. Stankoff, B. Gout, O. Thouvenot, E. Heinzlef, O. Sidhom, Y. Gouider, R. Csepany, T. Bourre, B. Al Khedr. A. Casez, O. Cabre, P. Montcuquet, A. Wahab, A. Camdessanche, JP. Maurousset, A. Patry, I. Hankiewicz, K. Pottier, C. Maubeuge, N. Labeyrie, C. Nifle, C. Coles, A. Malpas, CB. Vukusic, S. Butzkueven, H. Kalincik T. *Mult Scler.* doi: 10.1177/1352458520981300. [Online ahead of print – Jan 2021].
5. ***Effect of disease modifying therapy on disability in relapsing remitting multiple sclerosis over 15 years.*** Kalincik, T. Diouf, I. Sharmin, S. Malpas, C. Spelman, T. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Lugesesi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Jokubaitis, V. van der Walt, A. Grand'Maison, F. Sola, P. Ferraro, D. Shaygannejad, V. Alroughani, R. Hupperts, R. Terzi, M. Boz, C. Lechner-Scott, J. Pucci, E. Van Pesch, V. Granella, F. Bergamaschi. R. Spitaleri. D. Slee. M. Vucic. S. Ampapa, R. McCombe, P. Ramo-Tello, C. Prevost, J. Olascoaga, J. Cristiano, E. Barnett, M. Saladino, ML. Sanchez-Menoyo, JL. Hodgkinson, S. Rozsa, C. Hughes, S. Moore, F. Shaw, C. Butler, E. Skibina, O. Gray, O. Kermode, A. Csepany, T. Singhal, B.

Shuey, N. Pirooska, I. Taylor, B. Simo, M. Sirbu, CA. Sas, A. Butzkueven, H.; MSBase Study group. *Neurology*. (Feb 2021) 96(5): e783-e797. doi: 10.1212/WNL.0000000000011242.

6. **Treatment response score to glatiramer acetate or interferon beta-1a.** Bovis, F. Kalincik, T. Lublin, F. Cutter, G. Malpas, C. Horakova, D. Havrdova, EK. Trojano, M. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugesesi, A. Izquierdo, G. Eichau, S. Patti, F. Terzi, M. Grammond, P. Bergamaschi, R. Sola, P. Ferraro, D. Ozakbas, S. Iuliano, G. Boz, C. Hupperts, R. Grand'Maison, F. Oreja-Guevara, C. van Pesch, V. Cartechini, E. Petersen, T. Altintas, A. Soysal, A. Ramo-Tello, C. McCombe, P. Turkoglu, R. Butzkueven, H. Wolinsky, JS. Solaro, C. Sormani, MP. *Neurology*. (Jan 2021) 96(2): e214-e227. doi: 10.1212/WNL.0000000000010991.
7. **Delay from treatment start to full effect of immunotherapies for multiple sclerosis.** Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Onofrj, M. Lugesesi, A. Prat, A. Girard, M. Grammond, P. Sola, P. Ferraro, D. Ozakbas, S. Bergamaschi, R. Sá, MJ. Cartechini, E. Boz, C. Granella, F. Hupperts, R. Terzi, M. Lechner-Scott, J. Spitaleri, D. Van Pesch, V. Soysal, A. Olascoaga, J. Prevost, J. Aguera-Morales, E. Slee, M. Csepany, T. Turkoglu, R. Sidhom, Y. Gouider, R. Van Wijmeersch, B. McCombe, P. Macdonell, R. Coles, A. Malpas, CB. Butzkueven, H. Vukusic, S. Kalincik, T.; MSBase; OFSEP investigators. *Brain*. (Sept 2020) 143(9): 2742-2756. doi: 10.1093/brain/awaa231.
8. **Association of pregnancy with the onset of clinically isolated syndrome.** Nguyen, A. Vodehnalova, K. Kalincik, T. Signori, A. Havrdova, EK. Lechner-Scott, J. Skibina, OG. Eastaugh, A. Taylor, L. Baker, J. McGuinn, N. Rath, L. Maltby, V. Sormani, MP. Butzkueven, H. Van der Walt, A. Horakova, D. Jokubaitis, V.G. *JAMA Neurol*. doi: 10.1001/jamaneurol.2020.3324. [Online ahead of print – Sept 2020].
9. **Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis.** Lizak, N. Malpas, CB. Sharmin, S. Havrdova, EK. Horakova, D. Izquierdo, G. Eichau, S. Lugesesi, A. Duquette, P. Girard, M. Prat, A. Larochelle, C. Trojano, M. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Hupperts, R. Bergamaschi, R. Boz, C. Van Pesch, V. Spitaleri, D. Terzi, M. Kalincik, T. MSBase Study Group. *JAMA Neurol*. doi: 10.1001/jamaneurol.2020.2453. [Online ahead of print – Jul 2020].
10. **Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.** Kunchok, A. Lechner-Scott, J. Granella, F. Trojano, M. Alroughani, R. Sola, P. Ferraro, D. Lugesesi, A. Onofrj, M. Ozakbas, S. Izquierdo, G. Grammond, P. Luis Sanchez-Menoyo, J. Van Wijmeersch, B. Boz, C. Pucci, E. McCombe, P. Grand'Maison, F. Spitaleri, D. Vucic, S. Hupperts, R. Jokubaitis, V. Sormani, MP. Butzkueven, H. Kalincik, T.; MSBase Study Group. *Mult Scler*. doi: 10.1177/1352458520936823. [Online ahead of print – Jul 2020].
11. **Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.** Le, M. Malpas, C. Sharmin, S. Horáková, D. Havrdova, E. Trojano, M. Izquierdo, G. Eichau, S. Ozakbas, S. Lugesesi, A. Prat, A. Girard, M. Duquette, P. Larochelle, C. Alroughani, R. Bergamaschi, R. Sola, P. Ferraro, D. Grammond, P. Grand'Maison, F. Terzi, M. Boz, C. Hupperts, R. Butzkueven, H. Pucci, E. Granella, F. Van Pesch, V. Soysal, A. Yamout, BI. Lechner-Scott, J. Spitaleri, D. Ampapa, R. Turkoglu, R. Iuliano, G. Ramo-Tello, C. Sanchez-Menoyo, JL. Sidhom, Y. Gouider, R. Shaygannejad, V. Prevost, J. Altintas, A. Fragos, YD. McCombe, PA. Petersen, T. Slee, M. Barnett, MH. Vucic, S. Van Der Walt, A. Kalincik, T. *Mult Scler*. doi: 10.1177/1352458520926955. [Online ahead of print – Jun 2020].
12. **Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.** Lizak, N. Hodgkinson, S. Butler, E. Lechner-Scott, J. Slee, M. McCombe, PA. Shaw, C. Skibina, O.

Vucic, S. Shuey, N. Barnett, MH. Parratt, J. Butzkueven, H. Jack, D. Fabris, J. Kalincik, T. *Mult Scler.* doi: [10.1177/1352458520921087](https://doi.org/10.1177/1352458520921087) [Online ahead of print – Jun 2020].

13. **Early clinical markers of aggressive multiple sclerosis.** Malpas, C.B. Manouchehrinia, A. Sharmin, S. Roos, I. Horakova, D. Havrdova, E.K. Trojano, M. Izquierdo, G. Eichau, S. Bergamaschi, R. Sola, P. Ferraro, D. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Grand'Maison, F. Ozakbas, S. Van Pesch, V. Granella, F. Hupperts, R. Pucci, E. Boz, C. Sidhom, Y. Gouider, R. Spitaleri, D. Soysal, A. Petersen, T. Verheul, F. Karabudak, R. Turkoglu, R. Ramo-Tello, C. Terzi, M. Cristiano, E. Slee, M. McCombe, P. Macdonell, R. Fragoso, Y. Olascoaga, J. Altintas, A. Olsson, T. Butzkueven, H. Hillert, J. Kalincik, T. *Brain.* (May 2020) **143(5): 1400-1413.** doi: [10.1093/brain/awaa081](https://doi.org/10.1093/brain/awaa081).
14. **Timing of high-efficacy therapy for multiple sclerosis: a retrospective observation cohort study.** He, A. Merkel, B. Brown, JWL. Zhovits Ryerson, L. Kister, I. Malpas, CB. Sharmin, S. Horakova, D. Kubala Havrdova, E. Spelman, T. Izquierdo, G. Eichau, S. Trojano, M. Lugaresi, A. Hupperts, R. Sola, P. Ferraro, D. Lycke, J. Grand'Maison, F. Prat, A. Girard, M. Duquette, P. Larochelle, C. Svenningsson, A. Petersen, T. Grammond, P. Granella, F. Van Pesch, V. Bergamaschi, R. McGuigan, C. Coles, A. Hillert, J. Piehl, F. Butzkueven, H. Kalincik, T; MSBase study group. *Lancet Neurol.* (Apr 2020) **19(4): 307-316.** doi: [10.1016/S1474-4422\(20\)30067-3](https://doi.org/10.1016/S1474-4422(20)30067-3).
15. **Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.** Kunchok, A. Malpas, C. Nytrova, P. Havrdova, EK. Alroughani, R. Terzi, M. Yamout, B. Hor, JY. Karabudak, R. Boz, C. Ozakbas, S. Olascoaga, J. Simo, M. Granella, F. Patti, F. McCombe, P. Csepany, T. Singhal, B. Bergamaschi, R. Fragoso, Y. Al-Harbi, T. Turkoglu, R. Lechner-Scott, J. Laureys, G. Oreja-Guevara, C. Pucci, E. Sola, P. Ferraro, D. Altintas, A. Soysal, A. Vucic, S. Grand'Maison, F. Izquierdo, G. Eichau, S. Lugaresi, A. Onofrj, M. Trojano, M. Marriott, M. Butzkueven, H. Kister, I. Kalincik, T. *Mult Scler Relat Disord.* <http://dx.doi.org/10.1016/j.msard.2019.101868> [Epub ahead of print – Nov 2019].
16. **Risk of secondary progressive multiple sclerosis: A longitudinal study.** Fambiatos, A. Jokubaitis, V. Horakova, D. Kubala Havrdova, E. Trojano, M. Prat, A. Girard, M. Duquette, P. Lugaresi, A. Izquierdo, G. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Alroughani, R. Terzi, M. Hupperts, R. Boz, C. Lechner-Scott, J. Pucci, E. Bergamaschi, R. Van Pesch, V. Ozakbas, S. Granella, F. Turkoglu, R. Iuliano, G. Spitaleri, D. McCombe, P. Solaro, C. Slee, M. Ampapa, R. Soysal, A. Petersen, T. Sanchez-Menoyo, JL. Verheu, F. Prevost, J. Sidhom, Y. Van Wijmeersch, B. Vucic, S. Cristiano, E. Saladino, ML. Deri, N. Barnett, M. Olascoaga, J. Moore, F. Skibina, O. Gray, O. Fragoso, Y. Yamout, B. Shaw, C. Singhal, B. Shuey, N. Hodgkinson, S. Altintas, A. Al-Harbi, T. Csepany, T. Taylor, B. Hughes, J. Jun, JK. van der Walt, A. Spelman, T. Butzkueven, H. Kalincik, T. *Mult Scler.* (Jan 2020) **26(1): 79-90.** <https://doi.org/10.1177/1352458519868990>.
17. **The MSBase Registry: Informing Clinical Practice.** Kalincik, T. Butzkueven, H. *Mult Scler.* (Dec 2019) **25(14): 1828-1834.** <https://doi.org/10.1177/1352458519848965>.
18. **Comparison of fingolimod, dimethyl fumarate and teriflunomide for Multiple Sclerosis** Kalincik, T. Kubala Havrdova, E. Horakova, D. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Grammond, P. Onofrj, M. Lugaresi, A. Ozakbas, S. Kappos, L. Kuhle, J. Terzi, M. Lechner-Scott, J. Boz, C. Grand'Maison, F. Prevost, J. Sola, P. Ferraro, D. Granella, F. Trojano, M. Bergamaschi, R. Pucci, E. Turkoglu, R. McCombe, P.A. Pesch, V.V. Van Wijmeersch, B. Solaro, C. Ramo-Tello, C. Slee, M. Alroughani, R. Yamout, B. Shaygannejad, V. Spitaleri, D. Sánchez-Menoyo, J.L. Ampapa, R. Hodgkinson, S. Karabudak, R. Butler, E. Vucic, S. Jokubaitis, V. Spelman, T. Butzkueven, H. *J Neurol. Neurosurg Psychiatry* (Apr 2019) **90(4): 458-468.** <http://dx.doi.org/10.1136/jnnp-2018-319831>.

19. **Incidence of pregnancy and disease-modifying therapy exposure trends in women with Multiple Sclerosis: A contemporary cohort study.** Nguyen, A.L. Havrdova, E.K. Horakova, D. Izquierdo, G. Kalincik, T. van der Walt, A. Terzi, M. Alroughani, R. Duquette, P. Girard, M. Prat, A. Boz, C. Sola, P. Ferraro, D. Lugaresi, A. Lechner-Scott, J. Barnett, M. Grand'Maison, F. Grammond, P. Ramo-Tello, C. Turkoglu, R. McCombe, P. Pucci, E. Trojano, M. Granella, F. Spitaler, D. Van Pesch, V. Soysal, A. Oreja-Guevara, C. Verheul, F. Vucic, S. Hodgkinson, S. Slee, M. Ampapa, R. Prevost, J. Menoyo, J.L.S. Skibina, O. Solaro, C. Olascoaga, J. Shaw, C. Madsen, K.G. Naidoo, K. Hyde, R. Butzkueven, H. Jokubaitis, V.; MSBase Study Group. *Mult Scler Relat Disord.* (Feb 2019) 28:235-243. <http://dx.doi.org/10.1016/j.msard.2019.01.003>.
20. **Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.** Lorscheider, J., J. Kuhle, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, R. Hupperts, P. Duquette, M. Girard, A. Prat, F. Grand'Maison, P. Grammond, P. Sola, D. Ferraro, M. Trojano, C. Ramo-Tello, J. Lechner-Scott, E. Pucci, C. Solaro, M. Slee, V. van Pesch, J.L.S. Menoyo, A van der Walt, H. Butzkueven, L. Kappos, T. Kalincik, on behalf of the MSBase Study Group. *Eur J Neurol.* (Feb 2019) 26(2): 363-370. <http://dx.doi.org/10.1111/ene.13824>.
21. **Association of Initial Disease-Modifying Therapy with later conversion to Secondary Progressive Multiple Sclerosis.** Brown, J.W.L. Coles, A. Horakova, D. Havrdova, E. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Trojano, M. Lugaresi, A. Bergamaschi, R. Grammond, P. Alroughani, R. Hupperts, R. McCombe, P. Van Pesch, V. Sola, P. Ferraro, D. Grand'Maison, F. Terzi, M. Lechner-Scott, J. Flechter, S. Slee, M. Shaygannejad, V. Pucci, E. Granella, F. Jokubaitis, V. Willis, M. Rice, C. Scolding, N. Wilkins, A. Pearson, O.R. Ziemssen, T. Hutchinson, M. Harding, K. Jones, J. McGuigan, C. Butzkueven, H. Kalincik, T. Robertson, N; MSBase Study Group. *JAMA* (Jan 2019) 15;321(2): 175-187 <http://dx.doi.org/10.1001/jama.2018.20588>.
22. **Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis.** Hughes, J., V. Jokubaitis, A. Lugaresi, R. Hupperts, G. Izquierdo, A. Prat, M. Girard, P. Duquette, F. Grand'Maison, P. Grammond, P. Sola, D. Ferraro, C. Ramo-Tello, M. Trojano, M. Slee, V. Shaygannejad, C. Boz, J. Lechner-Scott, V. Van Pesch, E. Pucci, C. Solaro, F. Verheul, M. Terzi, F. Granella, D. Spitaleri, R. Alroughani, J. K. Jun, A. Fambiatos, A. Van der Walt, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. *JAMA Neurol.* (Nov 2018) 1;75(11):1407-1415. <http://dx.doi.org/10.1001/jamaneurol.2018.2109>
23. **Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis.** Min, M., T. Spelman, A. Lugaresi, C. Boz, D. Spitaleri, E. Pucci, F. Grand'Maison, F. Granella, G. Izquierdo, H. Butzkueven, J. L. Sanchez-Menoyo, M. Barnett, M. Girard, M. Trojano, P. Grammond, P. Duquette, P. Sola, R. Alroughani, R. Hupperts, S. Vucic, T. Kalincik, V. Van-Pesch and J. Lechner-Scott. *Mult Scler.* (Oct 2018) 24(12): 1569-1577. <http://dx.doi.org/10.1177/1352458518798147>
24. **Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.** Kalincik, T., V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. Butler, M. Slee, A. Kermodé, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueven on behalf of the MSBase Study Group. *Mult Scler.* (Oct 2018) 24(12):1617-1626. <http://dx.doi.org/10.1177/1352458517728812>.
25. **Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.** Kister, I., T. Spelman, F. Patti, P. Duquette, M. Trojano, G. Izquierdo, A. Lugaresi, P. Grammond, P. Sola, D. Ferraro, F. Grand'Maison, R. Alroughani, M. Terzi, C. Boz, R. Hupperts, J. Lechner-Scott, L. Kappos, E. Pucci, S.

26. **Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.** Signori, A., G. Izquierdo, A. Lugaresi, R. Hupperts, F. Grand'Maison, P. Sola, D. Horakova, E. Havrdova, A. Prat, M. Girard, P. Duquette, C. Boz, P. Grammond, M. Terzi, B. Singhal, R. Alroughani, T. Petersen, C. Ramo, C. Oreja-Guevara, D. Spitaleri, V. Shaygannejad, H. Butzkueven, T. Kalincik, V. Jokubaitis, M. Slee, R. Fernández Bolaños, J. L. Sanchez-Menoyo, E. Pucci, F. Granella, J. Lechner-Scott, G. Iuliano, S. Hughes, R. Bergamaschi, B. Taylor, F. Verheul, M. Edite Rio, M.P. Amato, S.A. Sajedi, N. Majdinasab, V. Van Pesch, M.P. Sormani, M. Trojano. *Mult Scler* (April 2018) 24(5): 642-652. <http://dx.doi.org/10.1177/1352458517703800>
27. **Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.** Fragoso, Y. D., T. Spelman, C. Boz, R. Alroughani, A. Lugaresi, S. Vucic, H. Butzkueven, M. Terzi, E. Havrdova, D. Horakova, F. Granella, J. Olascoaga, J. L. Sanchez-Menoyo, E. Pucci, M. Barnett, J. B. B. Brooks, J. Haartsen, on behalf of the MSBase Lymphopenia and Efficacy of Fingolimod Sub-Study Investigators. *Mult Scler Relat Disord.* (Jan 2018) 19: 105-108. <http://dx.doi.org/10.1016/j.msard.2017.11.018>
28. **Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.** Kalincik, T, A. Manouchehrinia, L. Sobisek, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, R. Hupperts, F. Grand'Maison, E. Pucci, C. Boz, R. Alroughani, V. Van Pesch, J. Lechner-Scott, M. Terzi, R. Bergamaschi, G. Iuliano, F. Granella, D. Spitaleri, V. Shaygannejad, C. Oreja-Guevara, M. Slee, R. Ampapa, F. Verheul, P. McCombe, J. Olascoaga, M. P. Amato, S. Vucic, S. Hodgkinson, C. Ramo-Tello, S. Flechter, E. Cristiano, C. Rozsa, F. Moore, J. L. Sanchez-Menoyo, M. L. Saladino, M. Barnett, J. Hillert, H. Butzkueven, on behalf of the MSBase Study Group. *Brain.* (Sep 2017) 140(9): 2426-2443. <http://dx.doi.org/10.1093/brain/awx185>
29. **Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.** Lorscheider, J., V.G. Jokubaitis, T. Spelman, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, M. Trojano, P. Duquette, M. Girard, A. Prat, F. Grand'Maison, P. Grammond, E. Pucci, C. Boz, P. Sola, D. Ferraro, D. Spitaleri, J. Lechner-Scott, M. Terzi, V. Van Pesch, G. Iuliano, R. Bergamaschi, C. Ramo-Tello, F. Granella, C. Oreja-Guevara, H. Butzkueven, T. Kalincik and the MSBase Study Group. *Neurology.* (Sep 2017) 89(10): 1050-1059. <http://dx.doi.org/10.1212/WNL.0000000000004330>.
30. **Quantifying risk of early relapse in patients with demyelinating events: Prediction in clinical practice.** Spelman, T., C. Meyniel, J.L. Rojas, A. Lugaresi, G. Izquierdo, F. Grand'Maison, C. Boz, R. Alroughani, E. Havrdova, D. Horakova, G. Iuliano, P. Duquette, M. Terzi, P. Grammond, R. Hupperts, J. Lechner-Scott, C. Oreja-Guevara, E. Pucci, F. Verheul, M. Fiol, V. Van Pesch, E. Cristiano, T. Petersen, F. Moore, T. Kalincik, V. Jokubaitis, M. Trojano, H. Butzkueven on behalf of the MSBasis (an MSBase Substudy) Investigators. *Mult Scler.* (Sep 2017) 23(10): 1346-1357. <http://dx.doi.org/10.1177/1352458516679893>
31. **Incidence and prevalence of NMOSD in Australia and New Zealand.** Bukhari, W., K. M. Prain, P. Waters, M. Woodhall, C. M. O'Gorman, L. Clarke, R. A. Silvestrini, C. S. Bundell, D. Abernethy, S. Bhuta, S. Blum, M. Boggild, K. Boundy, B. J. Brew, M. Brown, W. J. Brownlee, H. Butzkueven, W. M. Carroll, C. Chen, A. Coulthard, R. C. Dale, C. Das, K. Dear, M. J. Fabis-Pedrini, D. Fulcher, D. Gillis, S. Hawke, R. Heard, A. P. D. Henderson, S. Heshmat, S. Hodgkinson, S. Jimenez-Sanchez, T. Killpatrick, J. King, C. Kneebone, A. J. Kornberg, J. Lechner-Scott, M. W. Lin, C. Lynch, R. Macdonell, D. F. Mason, P. A. McCombe, M. P. Pender, J. A. Pereira, J. D. Pollard, S. W. Reddel, C. Shaw, J. Spies, J. Stankovich, I. Sutton, S. Vucic, M. Walsh, R. C. Wong, E. M. Yiu, M. H. Barnett, A. G. Kermodé, M. P. Marriott, J. D. E. Parratt, M. Slee, B. V. Taylor, E. Willoughby, R. J. Wilson, A. Vincent, S.

A. Broadly. *J Neurol Neurosurg Psychiatry*. (Aug 2017) 88(8): 632-638. <http://dx.doi.org/10.1136/jnnp-2016-314839>

32. **Prognostic indicators in pediatric clinically isolated syndrome.** Iaffaldano, P., M. Simone, G. Lucisano, A. Ghezzi, G. Coniglio, V. Brescia Morra, F. Patti, A. Lugaresi, G. Izquierdo, R. Bergamaschi, J. A. Cabrera-Gomez, C. Pozzilli, E. Millefiorini, R. Alroughani, C. Boz, E. Pucci, G. B. Zimatore, P. Sola, G. Lus, D. Maimone, C. Avolio, E. Cocco, S.A. Sajedi, G. Costantino, P. Duquette, V. Shaygannejad, T. Petersen, R. Fernández Bolaños, D. Paolicelli, C. Tortorella, T. Spelman, L. Margari, M.P. Amato, G. Comi, H. Butzkueven, M. Trojano, on behalf of the Italian iMedWeb Registry and the MSBase Registry. *Ann Neurol*. (May 2017) 81(5): 729-739. <http://dx.doi.org/10.1002/ana.24938>
33. **Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.** Kalincik, T., J.W.L. Brown, N. Robertson, M. Willis, N. Scolding, C.M. Rice, A. Wilkins, O. Pearson, T. Ziemssen, M. Hutchinson, C. McGuigan, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, R. Alroughani, E. Pucci, P. Sola, R. Hupperts, J. Lechner-Scott, M. Terzi, V. Van Pesch, C. Rozsa, F. Grand'Maison, C. Boz, F. Granella, M. Slee, D. Spitaleri, J. Olascoaga, R. Bergamaschi, F. Verheul, S. Vucic, P. McCombe, S. Hodgkinson, J.L. Sanchez-Menoyo, R. Ampapa, M. Simo, T. Csepany, C. Ramo, E. Cristiano, M. Barnett, H. Butzkueven, A. Coles on behalf of the MSBase Study Group. *Lancet Neurol* (Apr 2017) 16(4): 271-281. [http://dx.doi.org/10.1016/S1474-4422\(17\)30007-8](http://dx.doi.org/10.1016/S1474-4422(17)30007-8)
34. **Data quality evaluation for observational multiple sclerosis registries.** Kalincik, T., J. Kuhle, E. Pucci, J. I. Rojas, M. Tsolaki, C. A. Sirbu, M. Slee, H. Butzkueven, on behalf of the MSBase Scientific Leadership Group and MSBase Study Group. *Mult Scler*. (Apr 2017) 23(5): 647-655. <http://dx.doi.org/10.1177/1352458516662728>
35. **Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.** Lizak, N., A. Lugaressi, R. Alroughani, J. Lechner-Scott, M. Slee, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, P. Grammond, R. Hupperts, F. Grand'Maison, P. Sola, E. Pucci, R. Bergamaschi, C. Oreja-Guevara, V. Van Pesch, C. Ramo, D. Spitaleri, G. Iuliano, C. Boz, F. Granella, J. Olascoaga, F. Verheul, C. Rozca, E. Cristiano, S. Flechter, S. Hodgkinson, M.P. Amato, N. Deri, V. Jokubaitis, T. Spelman, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. *J Neurol Neurosurg Psychiatry*. (Mar 2017) 88(3): 196-203. <http://dx.doi.org/10.1136/jnnp-2016-313976>
36. **Contribution of different relapse phenotypes to disability in multiple sclerosis.** Stewart, T., T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, A. Lugaresi, F. Grand'Maison, P. Grammond, P. Sola, V. Shaygannejad, R. Hupperts, R. Alroughani, C. Oreja-Guevara, E. Pucci, C. Boz, J. Lechner-Scott, R. Bergamaschi, V. Van Pesch, G. Iuliano, C. Ramo, B. Taylor, M. Slee, D. Spitaleri, F. Granella, F. Verheul, P. McCombe, S. Hodgkinson, M. P. Amato, S. Vucic, O. Gray, E. Cristiano, M. Barnett, J. L. Sanchez- Menoyo, E. van Munster, M. L. Saladino, J. Olascoaga, J. Prevost, N. Deri, C. Shaw, B. Singhal, F. Moore, C. Rozsa, N. Shuey, O. Skibina, I. Kister, T. Petkovska-Boskova, R. Ampapa, A. Kermodé, H. Butzkueven, V. Jokubaitis, T. Kalincik on behalf of the MSBase Study Group. *Mult Scler* (Feb 2017) 23(2): 266-276. <http://dx.doi.org/10.1177/1352458516643392>
37. **Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.** Tao, C., S. Simpson Jr, I. van der Mei, L. Blizzard, E. Havrdova, D. Horakova, V. Shaygannejad, A. Lugaresi, G. Izquierdo, M. Trojano, P. Duquette, M. Girard, F. Grand'Maison, P. Grammond, R. Alroughani, M. Terzi, C. Oreja-Guevara, S.A. Sajedi, G. Iuliano, P. Sola, J. Lechner-Scott, V. Van Pesch, E. Pucci, R. Bergamaschi, M. Barnett, C. Ramo, B. Singhal, D. LA Spitaleri, M. Slee, F. Verheul, R. Fernández Bolaños, M.P. Amato, E. Cristiano, F. Granella, S. Hodgkinson, M. Fiol, O. Gray, P. McCombe, M.L. Saladino, J.L. Sanchez Menoyo, N. Shuey, S. Vucic, C. Shaw, N. Deri, W. Oleschko-Arruda, H. Butzkueven, T. Spelman, B.V. Taylor on behalf of the MSBase

Study Group. *J Neurol Neurosurg Psychiatry.* (Dec 2016) 87(12): 1343-1349.
<http://dx.doi.org/10.1136/jnnp-2016-314013>

38. ***Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.*** Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand'Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano, H. Butzkueven on behalf of the MSBase Study Group. *J Neurol Neurosurg Psychiatry.* (Oct 2016) 87(10): 1133-7.
<http://dx.doi.org/10.1136/jnnp-2016-313760>
39. ***Defining secondary progressive multiple sclerosis.*** Lorscheider, J., K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand'Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J. Lechner-Scott, R. Bergamaschi, C. Oreja-Guevara, G. Iuliano, V. Van Pesch, F. Granella, C. Ramo-Tello, D. Spitaleri, T. Petersen, M. Slee, F. Verheul, R. Ampapa, MP. Amato, P. McCombe, S. Vucic, JL. Sanchez Menoyo, E. Cristiano, MH. Barnett, S. Hodgkinson, J. Olascoaga, ML. Saladino, O. Gray, C. Shaw, F. Moore, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. *Brain.* (Sep 2016) 139(Pt 9): 2395-405.
<http://dx.doi.org/10.1093/brain/aww173>
40. ***Predictors of long-term disability accrual in relapse-onset multiple sclerosis.*** Jokubaitis, V.G., T. Spelman, T. Kalincik, J. Lorscheider, E. Havrdova, D. Horakova, P. Duquette, M. Girard, A. Prat, G. Izquierdo, P. Grammond, V. Van Pesch, E. Pucci, F. Grand'Maison, R. Hupperts, F. Granella, P. Sola, R. Bergamaschi, G. Iuliano, D. Spitaleri, C. Boz, S. Hodgkinson, J. Olascoaga, F. Verheul, D. Paolicelli, H. Butzkueven, A. Lugaresi and M. Trojano, for the MSBase Study Group. *Ann Neurol.* (Jul 2016) 80(1): 89-100.
<http://dx.doi.org/10.1002/ana.24682>
41. ***Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.*** Spelman, T., T. Kalincik, V. Jokubaitis, A. Zhang, F. Pellegrini, H. Weindl, S. Belachew, R. Hyde, F. Verheul, A. Lugaresi, E. Havrdova, D. Horakova, P. Grammond, P. Duquette, A. Prat, G. Iuliano, M. Terzi, G. Izquierdo, R. M. Hupperts, C. Boz, E. Pucci, G. Giuliani, P. Sola, D. L. Spitaleri, J. Lechner-Scott, R. Bergamaschi, F. Grand'Maison, F. Granella, L. Kappos, M. Trojano and H. Butzkueven, on behalf of the MSBase Investigators and the TOP Investigators. *Neurol Clin Pract.* (Apr 2016) 6(2): 102-115
<http://dx.doi.org/10.1212/CPJ.0000000000000227>
42. ***Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.*** Spelman, T., L. Mekhael, T. Burke, H. Butzkueven, S. Hodgkinson, E. Havrdova, D. Horakova, P. Duquette, G. Izquierdo, F. Grand'Maison, P. Grammond, M. Barnett, J. Lechner-Scott, R. Alroughani, M. Trojano, A. Lugaresi, F. Granella, E. Pucci and S. Vucic on behalf of the MSBase Study Group. *Eur J Neurol.* (Apr 2016) 23(4): 729-736.
<http://dx.doi.org/10.1111/ene.12929>
43. ***The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.*** Warrender-Sparkes, M., T. Spelman, G. Izquierdo, M. Trojano, A. Lugaresi, F. Grand'Maison, E. Havrdova, D. Horakova, C. Boz, C. Oreja-Guevara, R. Alroughani, G. Iuliano, P. Duquette, M. Girard, M. Terzi, R. Hupperts, P. Grammond, T. Petersen, R. Fernández Bolaños, M. Fiol, E. Pucci, J. Lechner-Scott, F. Verheul, E. Cristiano, V. Van Pesch, T. Petkovska-Boskova, F. Moore, I. Kister, R. Bergamaschi, M. L. Saladino, M. Slee, M. Barnett, M. P. Amato, C. Shaw, N. Shuey, C. Young, O. Gray, L. Kappos, H. Butzkueven, T. Kalincik and V. Jokubaitis, on behalf of the MSBase study group. *Mult Scler.* (Apr 2016) 22 (4): 520-532.
<http://dx.doi.org/10.1177/1352458515594041>
44. ***Defining reliable disability outcomes in multiple sclerosis.*** Kalincik, T., G. Cutter, T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F.

Grand'Maison, P. Grammond, R. Hupperts, C. Oreja-Guevara, C. Boz, E. Pucci, R. Bergamaschi, J. Lechner-Scott, R. Alroughani, V. Van Pesch, G. Iuliano, R. Fernández Bolaños, C. Ramo, M. Terzi, M. Slee, D. Spitaleri, F. Verheul, E. Cristiano, J. L. Sánchez-Menoyo, M. Fiol, O. Gray, J. A. Cabrera-Gomez, M. Barnett, H. Butzkueven, on behalf of the MSBase study group. *Brain*. (Nov 2015) 138 (Pt 11): 3287-98. <http://dx.doi.org/10.1093/brain/awv258>

45. **Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.** Kalincik, T., V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, A. Lugaresi, C. Oreja-Guevara, R. Bergamaschi, R. Hupperts, F. Grand'Maison, E. Pucci, V. Van Pesch, C. Boz, G. Iuliano, R. Fernández Bolaños, S. Flechter, D. Spitaleri, E. Cristiano, F. Verheul, J. Lechner-Scott, M. P. Amato, J. A. Cabrera-Gomez, M. L. Saladino, M. Slee, F. Moore, O. Gray, M. Paine, M. Barnett, E. Havrdova, D. Horakova, T. Spelman, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. *Mult Scler* (Aug 2015) 21(9): 1159-71. <http://dx.doi.org/10.1177/1352458514559865>
46. **Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry.** Rojas, J. I., L. Patrucco, M. Trojano, A. Lugaresi, G. Izquierdo, H. Butzkueven, V. Jokubaitis, P. Duquette, M. Girard, F. Grand'Maison, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. Van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, R. Fernández Bolaños, D. Poehlau, M. L. Saladino, L. Den Braber-Moerland, N. Deri, W. Oleschko-Arruda, J. A. Cabrera-Gomez, M. Paine, N. Vella, I. Kister, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, E. A. Bacile Bacile, V. Santiago, E. Cristiano, on behalf of the MSBase study group. *Mult Scler J Exp Transl Clin*. (Aug 2015) <http://dx.doi.org/10.1177/2055217315600193>
47. **Male Sex is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.** Ribbons, K. A., P. McElduff, C. Boz, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, F. Grand'Maison, R. Hupperts, P. Grammond, C. Oreja-Guevara, T. Petersen, R. Bergamaschi, G. Giuliani, M. Barnett, V. Van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaños, M. L. Saladino, M. E. Rio, J. Cabrera-Gomez, H. Butzkueven, E. van Munster, L. Den Braber-Moerland, D. La Spitaleri, A. Lugaresi, V. Shaygannejad, O. Gray, N. Deri, R. Alroughani and J. Lechner-Scott. *PLoS One* (Jun 2015) 10(6):e0122686. <http://dx.doi.org/10.1371/journal.pone.0122686>
48. **BREMSO: a simple score to predict early the natural course of multiple sclerosis.** Bergamaschi, R., C. Montomoli, G. Mallucci, A. Lugaresi, G. Izquierdo, F. Grand'Maison, P. Duquette, V. Shaygannejad, R. Alroughani, P. Grammond, C. Boz, G. Iuliano, C. Zwanikken, T. Petersen, J. Lechner-Scott, R. Hupperts, H. Butzkueven, E. Pucci, C. Oreja-Guevara, E. Cristiano, M. P. Pia Amato, E. Havrdova, R. Fernández Bolaños, T. Spelman and M. Trojano. *Eur J Neurol* (Jun 2015) 22(6): 981-9. <http://dx.doi.org/10.1111/ene.12696>
49. **Predictors of disability worsening in clinically isolated syndrome.** Jokubaitis, V. J., T. Spelman, T. Kalincik, G. Izquierdo, F. Grand'Maison, P. Duquette, M. Girard, A. Lugaresi, P. Grammond, R. Hupperts, J. Cabrera-Gomez, C. Oreja-Guevara, C. Boz, G. Giuliani, R. Fernández Bolaños, G. Iuliano, J. Lechner-Scott, F. Verheul, V. Van Pesch, T. Petkovska-Boskova, M. Fiol, F. Moore, E. Cristiano, R. Alroughani, R. Bergamaschi, M. Barnett, M. Slee, N. Vella, J. Herbert, C. Shaw, M. L. Saladino, M. P. Amato, D. Liew, D. Paolicelli, H. Butzkueven & M. Trojano, on behalf of the MSBasis Study Group. *Ann Clin Transl Neurol* (May 2015) 2(5): 479-91. <http://dx.doi.org/10.1002/acn3.187>
50. **Comparative efficacy of switching to natalizumab in active multiple sclerosis.** Spelman, T., T. Kalincik, A. Zhang, F. Pellegrini, H. Wiendl, L. Kappos, L. Tsvetkova, S. Belachew, R. Hyde, F. Verheul, F. Grand-Maison, G. Izquierdo, P. Grammond, P. Duquette, A. Lugaresi, J. Lechner-Scott, C. Oreja-Guevara, R. Hupperts, T. Petersen, M. Barnett, M. Trojano, & H. Butzkueven, on behalf of the MSBase Investigators and the TOP Investigators. *Ann Clin Transl Neurol* (Apr 2015) 2(4): 373-87. <http://dx.doi.org/10.1002/acn3.180>

51. **Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.** He, A., T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, A. Lugaresi, G. Izquierdo, P. Grammond, P. Duquette, M. Girard, E. Pucci, G. Iuliano, R. Alroughani, C. Oreja-Guevara, R. Fernández Bolaños, F. Grand'Maison, P. Sola, D. Spitaleri, F. Granella, M. Terzi, J. Lechner-Scott, V. Van Pesch, R. Hupperts, J. L. Sánchez-Menoyo, S. Hodgkinson, C. Rozsa, F. Verheul, H. Butzkueven, T. Kalincik; for the MSBase Study Group. *JAMA Neurol* (Apr 2015) **72(4): 405-13**. <http://dx.doi.org/10.1001/jamaneurol.2014.4147>
52. **Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.** Kalincik, T., D. Horakova, T. Spelman, V. Jokubaitis, M. Trojano, A. Lugaresi, G. Izquierdo, C. Rozsa, P. Grammond, R. Alroughani, P. Duquette, M. Girard, E. Pucci, J. Lechner-Scott, M. Slee, R. Fernández Bolaños, F. Grand'Maison, R. Hupperts, F. Verheul, S. Hodgkinson, C. Oreja-Guevara, D. Spitaleri, M. Barnett, M. Terzi, R. Bergamaschi, P. McCombe, J. Sanchez-Menoyo, M. Simo, T. Csepany, G. Rum, C. Boz, E. Havrdova, H. Butzkueven; on behalf of the MSBase Study Group. *Ann Neurol* (Mar 2015) **77(3): 425-35**. <http://dx.doi.org/10.1002/ana.24339>
53. **Seasonal variation of relapse rate in multiple sclerosis is latitude-dependent.** Spelman, T., O. Gray, M. Trojano, T. Petersen, G. Izquierdo, A. Lugaresi, R. Hupperts, R. Bergamaschi, P. Duquette, P. Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja-Guevara, M. Barnett, F. Grand'Maison, M. E. Rio, J. Lechner-Scott, V. Van Pesch, R. Fernández Bolaños, S. Flechter, L. Den Braber-Moerland, G. Iuliano, M. P. Amato, M. Slee, E. Cristiano, M.L. Saladino, M. Paine, N. Vella, K. Kasa, N. Deri, J. Herbert, F. Moore, T. Petkovska-Boskova, R. Alroughani, A. Savino, C. Shaw, S. Vucic, V. Santiago, E. A. Bacile, E. Skromne, D. Poehlau, J. A. Cabrera-Gomez, R. Lucas and H. Butzkueven. *Ann Neurol* (Dec 2014) **76(6): 880-90**. <http://dx.doi.org/10.1002/ana.24287>
54. **Risk of relapse phenotype recurrence in multiple sclerosis.** Kalincik, T., K. Buzzard, V. G. Jokubaitis, M. Trojano, P. Duquette, I. Guillermo, M. Girard, A. Lugaresi, P. Grammond, F. Grand'Maison, C. Oreja-Guevara, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, G. Iuliano, J. Lechner-Scott, M. Barnett, R. Bergamaschi, V. Van Pesch, M. P. Amato, E. van Munster, R. Fernández Bolaños, F. Verheul, M. Fiol, E. Cristiano, M. Slee, M. E. Rio, D. L. A. Spitaleri, R. Alroughani, O. Gray, M. L. Saladino, S. Flechter, J. Herbert, J. A. Cabrera- Gomez, N. Vella, M. Paine, C. Shaw, F. Moore, S. Vucic, A. Savino, B. Singhal, T. Pekovska-Boskova, J. Parratt, C-A. Sirbu, C. Rozsa, D. Liew, H. Butzkueven, on behalf of the MSBase study group. *Mult Scler* (Oct 2014) **20(11): 1511-22**. <http://dx.doi.org/10.1177/1352458514528762>
55. **Predictors and dynamics of postpartum relapses in women with multiple sclerosis.** Hughes, S. E., T. Spelman, O. M. Gray, C. Boz, M. Trojano, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand'Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. Van Pesch, M. P. Amato, G. Iuliano, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaños, D. Poehlau, M. L. Saladino, N. Deri, J. Cabrera-Gomez, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, G. McDonnell, S. A. Hawkins, F. Kee, H. Butzkueven on behalf of the MSBase study group. *Mult Scler* (May 2014) **20(6): 739-46**. <http://dx.doi.org/10.1177/1352458513507816>
56. **Fingolimod after natalizumab and the risk of short-term relapse.** Jokubaitis, V. G., V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, R. Alroughani, J. Lechner-Scott, A. Lugaresi, P. Duquette, M. Girard, M. Barnett, F. Grand'Maison, M. Trojano, M. Slee, G. Giuliani, C. Shaw, C. Boz, D. L. A. Spitaleri, F. Verheul, J. Haartsen, D. Liew, H. Butzkueven on behalf of the MSBase study group. *Neurology* (Apr 2014) **82(14): 1204-11**. <http://dx.doi.org/10.1212/WNL.0000000000000283>
57. **Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.** Kalincik, T., V. Vivek, V. Jokubaitis, J. Lechner-Scott, M. Trojano, G. Izquierdo, A. Lugaresi, F. Grand'Maison, R. Hupperts, C. Oreja-Guevara, R. Bergamaschi, G. Iuliano, R. Alroughani, V. Van Pesch, M. P. Amato, M. Slee, F. Verheul, R. Fernández Bolaños, M. Fiol, D. L. A. Spitaleri, E. Cristiano, O. Gray, J. A. Cabrera-Gomez, V. Shaygannejad, J. Herbert, S. Vucic, M. Needham, T. Petkovska-Boskova, C-A. Sirbu, P. Duquette, M. Girard, P. Grammond, C. Boz, G. Giuliani, M. E. Rio, M. Barnett, S. Flechter, F. Moore, B. Singhal, E. A. Bacile, M. L. Saladino, C. Shaw,

E. Skromne, D. Poehlau, N. Vella, T. Spelman, D. Liew, T. J. Kilpatrick, H. Butzkueven on behalf of the MSBase Study Group. *Brain* (Dec 2013) 136(Pt 12): 3609-17. <http://dx.doi.org/10.1093/brain/awt281>

58. **Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.** Kalincik, T., T. Spelman, M. Trojano, P. Duquette, G. Izquierdo, P. Grammond, A. Lugaresi, R. Hupperts, E. Cristiano, V. Van Pesch, F. Grand'Maison, D. L. A. Spitaleri, M. E. Rio, S. Flechter, C. Oreja-Guevara, G. Giuliani, A. Savino, M. P. Amato, T. Petersen, R. Fernández Bolaños, R. Bergamaschi, G. Iuliano, C. Boz, J. Lechner-Scott, N. Deri, O. Gray, F. Verheul, M. Fiol, M. Barnett, E. Van Munster, V. Santiago, F. Moore, M. Slee, M. L. Saladino, R. Alroughani, C. Shaw, K. Kasa, T. Petkovska-Boskova, L. den Braber-Moerland, J. Chapman, E. Skromne, J. Herbert, D. Poehlau, M. Needham, E. A. Bacile Bacile, W. O. Arruda, M. Paine, B. Singhal, S. Vucic, J. A. Cabrera-Gomez, H. Butzkueven, on behalf of the MSBase Study Group. *PLoS One* (May 2013) 8(5):e63480. <http://dx.doi.org/10.1371/journal.pone.0063480>
59. **Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study.** Iuliano, G., C. Boz, E. Cristiano, P. Duquette, A. Lugaresi, C. Oreja-Guevara and V. Van Pesch. *J Neurol* (May 2013) 260(5):1258-62. <http://dx.doi.org/10.1007/s00415-012-6785-y>
60. **Fluctuations of MS births and UV-light exposure.** Verheul, F., J. Smolders, M. Trojano, V. Lepore, C. Zwanikken, M. P. Amato, F. Grand'Maison, H. Butzkueven, M. Marrosu, P. Duquette, G. Comi, G. Izquierdo, P. Grammond, G. Lus, T. Petersen, R. Bergamaschi, G. Giuliani, C. Boz, G. Coniglio, V. Van Pesch, J. Lechner-Scott, P. Cavalla, F. Granella, C. Avolio, M. Fiol, D. Poehlau, M. L. Saladino, P. Gallo, N. Deri, W. Oleschko Arruda, M. Paine, M. Ferro, M. Barnett, J. A. Cabrera-Gomez, M. Slee, F. Moore, C. Shaw, T. Petkovska-Boskova, M. Rutherford, O. Engelsen, J. Damoiseaux and R. Hupperts. *Acta Neurol Scand* (May 2013) 127(5):301-8. <http://dx.doi.org/10.1111/ane.12007>
61. **The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.** Jokubaitis, V. G., T. Spelman, J. Lechner-Scott, M. Barnett, C. Shaw, S. Vucic, D. Liew, H. Butzkueven, M. Slee, on behalf of the Australian MSBase Study Group. *PLoS One* (Mar 2013) 8(3):e59694. <http://dx.doi.org/10.1371/journal.pone.0059694>
62. **Geographical variations in sex ratio trends over time in multiple sclerosis.** Trojano, M., G. Lucchese, G. Graziano, B. V. Taylor, S. Simpson, Jr., V. Lepore, F. Grand'Maison, P. Duquette, G. Izquierdo, P. Grammond, M. P. Amato, R. Bergamaschi, G. Giuliani, C. Boz, R. Hupperts, V. Van Pesch, J. Lechner-Scott, E. Cristiano, M. Fiol, C. Oreja-Guevara, M. L. Saladino, F. Verheul, M. Slee, D. Paolicelli, C. Tortorella, M. D'Onghia, P. Iaffaldano, V. Drenzo, H. Butzkueven on behalf of the MSBase Study Group, the New Zealand MS Prevalence Study Group. *PLoS One* (Oct 2012) 7(10):e48078. <http://dx.doi.org/10.1371/journal.pone.0048078>
63. **Increasing age at disability milestones among MS patients in the MSBase registry.** Kister, I., E. Chamot, G. Cutter, T. E. Bacon, V. G. Jokubaitis, S. E. Hughes, O. M. Gray, M. Trojano, G. Izquierdo, F. Grand'Maison, P. Duquette, A. Lugaresi, P. Grammond, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, C. Oreja-Guevara, G. Iuliano, J. Lechner-Scott, R. Bergamaschi, M. E. Rio, F. Verheul, M. Fiol, V. van Pesch, M. Slee, H. Butzkueven, J. Herbert and the MSBase Investigators. *J Neurol Sci* (Jul 2012) 318(1-2): 94-9. <http://dx.doi.org/10.1016/j.jns.2012.03.017>
64. **The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.** Lechner-Scott, J., B. Spencer, T. de Malmanche, J. Attia, M. Fitzgerald, M. Trojano, F. Grand'Maison, J. A. Gomez, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, C. Boz, G. Giuliani, V. van Pesch, G. Iuliano, M. Fiol, E. Cristiano, F. Verheul, M. L. Saladino, M. Slee, M. Barnett, N. Deri, S. Flechter, N. Vella, C. Shaw, J. Herbert, F. Moore, T. Petkovska-Boskova, V. Jokubaitis, H. Butzkueven for the MSBase study group. *Mult Scler* (Jul 2012) 18(7): 974-82. <http://dx.doi.org/10.1177/1352458511431729>

65. **Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.** Meyniel, C., T. Spelman, V. G. Jokubaitis, M. Trojano, G. Izquierdo, F. Grand'Maison, C. Oreja-Guevara, C. Boz, A. Lugaresi, M. Girard, P. Grammond, G. Iuliano, M. Fiol, J. A. Cabrera-Gomez, R. Fernández Bolaños, G. Giuliani, J. Lechner-Scott, E. Cristiano, J. Herbert, T. Petkovska-Boskova, R. Bergamaschi, V. van Pesch, F. Moore, N. Vella, M. Slee, V. Santiago, M. Barnett, E. Havrdova, C. Young, C-A. Sirbu, M. Tanner, M. Rutherford, H. Butzkueven, on behalf of the MSBasis Study Group. *PLoS One* (Jun 2012) 7(6):e38661. <http://dx.doi.org/10.1371/journal.pone.0038661>
66. **The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase registry.** Hughes, S., T. Spelman, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand'Maison, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, R. Bergamaschi, G. Giuliani, M. E. Rio, J. Lechner-Scott, V. van Pesch, G. Iuliano, M. Fiol, F. Verheul, M. Barnett, M. Slee, J. Herbert, I. Kister, N. Vella, F. Moore, T. Petkovska-Boskova, V. Shaygannejad, V. Jokubaitis, G. McDonnell, S. Hawkins, F. Kee, O. Gray, H. Butzkueven, on behalf of the MSBase Study Group. *J Neurol Neurosurg Psychiatry* (Mar 2012) 83(3): 305-10. <http://dx.doi.org/10.1136/jnnp-2011-301051>
67. **MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.** Butzkueven, H., J. Chapman, E. Cristiano, F. Grand'Maison, M. Hoffmann, G. Izquierdo, D. Jolley, L. Kappos, T. Leist, D. Pöhlau, V. Rivera, M. Trojano, F. Verheul and J-P. Malkowski. *Mult Scler* (Dec 2006) 12(6): 769-74.